Work Here?
Overview
Company Does Not Provide H1B Sponsorship
TandemAI provides a cloud-based platform for pre-clinical drug discovery called TandemViz. It serves researchers at pharmaceutical companies and academic institutions by offering a suite of computational tools, AI, and supercomputing to simulate how drugs interact with proteins at the molecular level. The platform is accessed through a web interface, where users run dynamic physics-based molecular simulations to visualize drug-protein interactions and generate predictive models for efficacy and safety. TandemAI differentiates itself by offering a Discovery as a Service model that makes advanced drug-discovery tools widely accessible through subscriptions and service contracts, combining expertise from data science, physics, biology, and chemistry to speed up the research process. The company's goal is to democratize access to advanced computational tools, accelerate the discovery of therapeutic candidates, and improve the success rate of pre-clinical studies for patients in need.
About Tandem
Industries
Enterprise Software
AI & Machine Learning
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Series A
Total Funding
$82M
Headquarters
New York City, New York
Founded
2021
Simplify's Take
What believers are saying
- $22M Series A extension on November 19, 2025, funds AI models and wet lab expansion.
- TandemViz integrates experimental data from external repositories, boosting research efficiency.
- Prior $35M Series A in 2023 and $25M seed fuel computational platform scaling.
What critics are saying
- Schrödinger dominates with superior simulations, capturing Takeda and Bristol Myers Squibb clients.
- Exscientia nominates candidates 5x faster, eroding share via Sanofi and GSK deals.
- Perpetual Medicines merger causes 20-30% client attrition from workflow disruptions.
What makes Tandem unique
- TandemAI integrates AI, physics-based simulations, and in-house wet labs into TandemViz platform.
- TandemAI offers Discovery as a Service with FTE pricing and SaaS licenses for seamless collaboration.
- Merger with Perpetual Medicines on July 10, 2025, adds peptide drug discovery to small molecules.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$82M
Above
Industry Average
Funded Over
3 Rounds
Industry standards
Growth & Insights and Company News
6 month growth
↓ -4%1 year growth
↓ -2%2 year growth
↓ -5%TandemAI has secured a $22 million Series A extension to enhance its AI-driven drug discovery platform, raising over $80 million since its founding in October 2021. The company, with over 300 professionals, has developed more than ten candidates for clinical development and partnered with four top multinational pharmaceutical companies. The funding will support AI and computational physics model development and wet lab expansion, following a merger with Perpetual Medicines.
TandemAI Closes $22M Series A Extension Round
TandemAI secures $22M Series A extension. The financing will help the company further develop its drug discovery platform. TandemAI has secured a $22 million Series A extension to further develop its drug discovery platform, which combines advanced AI, physics-based computational methods, and wet lab capabilities. The round included both new and existing investors. Since its founding in October 2021, the company has raised over $80M. With a team of more than 300 professionals, TandemAI's AI-powered, fully integrated drug discovery engine has delivered over ten candidates that are now in - or soon to enter - clinical development. The company has also partnered with four of the world's top ten multinational pharmaceutical companies, building a network of more than 150 global partners and clients. "The financing is a strong vote of confidence in our progress to date and in our strategy," said Jeff He, co-founder and CEO of TandemAI. "This funding will support AI and computational physics-based model development for multiple modalities, as well as wet lab capacity expansion to accommodate our rapidly growing client base."
TandemAI, a company transforming drug discovery with state-of-the-art AI and physics-based technologies integrated with full wet lab capabilities, and Perpet...
Tandem's AI integrates with Accurx's platform to instantly summarise consultations and reduce documentation time.
There are no jobs for Tandem right now.
Find jobs on Simplify and start your career today
About Tandem
Industries
Enterprise Software
AI & Machine Learning
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Series A
Total Funding
$82M
Headquarters
New York City, New York
Founded
2021
There are no jobs for Tandem right now.
Find jobs on Simplify and start your career today